Yale-led trial shows significant disease-free survival in NSCLC

Yale receives renewed lung cancer SPORE grant from NCI

Yale Cancer Center’s Specialized Program of Research Excellence in Lung Cancer was awarded a renewal grant from NCI for year 11 of the program.

September 19, 2025

Vol.51 No.34

Clinical Roundup

Libtayo + chemo shows significant improvement in OS for advanced NSCLC, phase III EMPOWER-Lung 3 trial shows

Libtayo (cemiplimab) plus chemotherapy demonstrates a more than double five-year overall survival rate of 19.4%, compared to 8.8% with chemotherapy alone, according to late-breaking data from exploratory analyses at World Conference on Lung Cancer.

September 19, 2025

Vol.51 No.34

In Brief

Tracy Battaglia named associate director of COE at Yale

Tracy Battaglia joined Yale Cancer Center’s Community Outreach and Engagement serving as associate director.

September 12, 2025

Vol.51 No.33

Drugs & Targets

FDA grants Hernexeo Breakthrough Therapy designation as first line use for HER2-mutant advanced NSCLC

FDA granted Breakthrough Therapy designation to Hernexeos (zongertinib tablets) for first-line treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations.

September 12, 2025

Vol.51 No.33

In Brief

Arjan Gower receives NCCN grant to study a targeted therapy for early-stage NSCLC with rare EGFR mutations

Arjan Gower, a hematologist/oncologist at the UCLA Health Jonsson Comprehensive Cancer Center, received a $950,000 grant from the National Comprehensive Cancer Network and Taiho Oncology Inc. to help launch a multi-institutional clinical trial to test zipalertinib, an investigational drug that targets specific EGFR mutations, including Exon 20 insertions, which are known to drive cancer growth and resist standard treatments.

July 11, 2025

Vol.51 No.27

Clinical Roundup

A post-treatment blood test could inform future cancer therapy decisions, study shows

In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that measures the presence of cancer-derived molecules in the blood of patients with lung cancer years after their treatment.

March 21, 2025

Vol.51 No.11

Yale-led trial shows significant disease-free survival in NSCLC

YOU MAY BE INTERESTED IN

Yale receives renewed lung cancer SPORE grant from NCI

Libtayo + chemo shows significant improvement in OS for advanced NSCLC, phase III EMPOWER-Lung 3 trial shows

Tracy Battaglia named associate director of COE at Yale

FDA grants Hernexeo Breakthrough Therapy designation as first line use for HER2-mutant advanced NSCLC

Arjan Gower receives NCCN grant to study a targeted therapy for early-stage NSCLC with rare EGFR mutations

A post-treatment blood test could inform future cancer therapy decisions, study shows

Renew today!

Subscriber content

Never miss an issue!

Login